别嘌醇联合非布司他对高尿酸慢性肾病患者尿酸水平及肾功能的影响

Effects of allopurinol combined with febuxostat on the uric acid and renal function in patients with high uric acid chronic kidney disease

目的观察别嘌醇联合非布司他对高尿酸(HUA)慢性肾病患者尿酸(UA)水平及肾功能的影响。方法将126例高尿酸慢性肾病患者随机分为对照组和试验组,每组63例。对照组给予别嘌醇0. 25 g,每天1次,口服;试验组在对照组的基础上给予非布司他40 mg,每天1次,口服。2组均治疗6个月。观察2组患者的肾功能、电解质和生化指标变化。结果治疗后,对照组与试验组UA分别为(466. 62±95. 74),(417. 96±75. 48)μmol·L-1,血钾水平分别为(1. 64±1. 02),(1. 27±0. 87) mmol·L-1,血钠分别为(120. 42±3. 01),(118. 78±2. 69) mmol·L-1,血清中性粒细胞明胶酶相关脂质运载蛋白(NGAL)分别为(621. 84±167. 52),(688. 02±183. 01) ng·mL-1,差异均有统计学意义(均P <0. 05)。结论非布司他联合别嘌醇治疗高尿酸慢性肾病能有效改善患者的肾功及生化指标,纠正电解质失衡,延缓肾损害进展。

Objective To explore the effects of allopurinol combined with febuxostat on uric acid(UA)and renal function in patients with high uric acid(HUA)chronic kidney disease.Methods A total of 126 cases with HUA chronic kidney disease were randomly divided into control group and treatment group,63 cases in each group.Control group was treated with allopurinol 0.25 g,1 time per day,oral,and treatment group was treated with febuxostat 40 mg,1 time per day,oral,on the basis of control group.The levels of renal function,electrolyte and biochemical indexes were observed between the two groups.Results The serum levels of UA in control group and treatment group after treatment were(466.62±95.74),(417.96±75.48)μmol·L-1,potassium were(1.64±1.02),(1.27±0.87)mmol·L-1,the serum levels of sodium were(120.42±3.01),(118.78±2.69)mmol·L-1,the serum neutrophil gelatinase-associated lipocalin(NGAL)levels were(621.84±167.52),(688.02±183.01)ng·mL-1,all with significant difference(all P<0.05).Conclusion Febuxostat combined with allopurinol in the treatment of HUA chronic kidney disease can effectively improve renal function and biochemical indexes,correct electrolyte imbalance and slow down the progression of renal damage.